[Adverse effects of conventional DMARDs and biologic DMARDs].
Suzuki
Yasuo
Y
Division of Rheumatology, Tokai University School of Medicine.
Saito
Eiko
E
Wakabayashi
Takayuki
T
Suwa
Akira
A
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003545:Cysteine / Q000009:adverse effects / Q000031:analogs & derivatives; D003875:Drug Eruptions / Q000209:etiology*; D004342:Drug Hypersensitivity / Q000209:etiology; D006402:Hematologic Diseases / Q000139:chemically induced*; D006801:Humans; D007154:Immune System Diseases / Q000139:chemically induced; D000069285:Infliximab; D007555:Isoxazoles / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced*; D000077339:Leflunomide; D008171:Lung Diseases / Q000139:chemically induced*; D008727:Methotrexate / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007555:Isoxazoles; D000069285:Infliximab; D000077339:Leflunomide; D003545:Cysteine; C026535:bucillamine; D008727:Methotrexate